Microneedle Patch Could Offer Alternative Mode of Vaccination

Share this content:
Microneedle Patch Could Offer Alternative Mode of Vaccination
Microneedle Patch Could Offer Alternative Mode of Vaccination

TUESDAY, April 28, 2015 (HealthDay News) -- A microneedle patch may be an easier, safer, and more convenient way to vaccinate more people worldwide against measles and other vaccine-preventable diseases, new research suggests.

Being developed by the U.S. Centers for Disease Control and Prevention and the Georgia Institute of Technology, the small patch is lined on one side with 100 tiny needles made of polymer, sugar, and vaccine. These microneedles are less than a millimeter long and are pressed into the skin with a thumb, the CDC researchers said.

A study conducted by the CDC and Georgia Tech showed the patch produces a strong immune response in rhesus macaque monkeys without adverse effects. That finding cleared the way for trials involving people by 2017, the researchers said. When the patch is applied, the microneedles enter the outer layers of the skin and dissolve within a few minutes, releasing the vaccine. Afterward, the patch can be thrown away, the researchers added.

The patch is no more costly than conventional syringe vaccines, and health workers with minimal training can administer the patch. It can also be stored, distributed, and discarded more easily than conventional vaccines, the researchers said. Another benefit to the patch is that it can be stored more efficiently and stays viable even at more extreme temperatures. The researchers noted this would help health workers provide the measles vaccine to those living in remote areas. The patch also eliminates the risks associated with accidental needlesticks, they added.

More Information

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths